The article, a collaborative effort among experts in genetics, pharmacy, medicine, and primary care, explores how genetic testing for detecting monogenic diabetes type MODY2 (Project iMOgene) can be integrated into primary care.
This pilot study aims to understand how these technologies can transform patient diagnosis and management, while facilitating access to more personalized medicine.
It’s important to note that MODY2 diabetes leads to mild hyperglycemia without long-term cardiovascular complications in affected individuals. This genetic condition is often mistaken for type 1 or type 2 diabetes, which can result in unnecessary medication use.
Comments